RxDoctor Payments Data

Eric Yang, MD

Cardiovascular Disease · Los Angeles, CANPI 1205028644

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $23,238 of the $36,615 with a category attached, or 63.5%. Edwards Lifesciences accounts for 71.9% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $12,024, more than ten times the $28 reported in 2019. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,615in general payments, 2019–2025

Across 72 payments — averaging $508.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$26K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
  • Abbott$926
  • AstraZeneca$713
  • Medtronic$288
  • Abiomed$254
  • plus $570 from 10 others
$313,355in research payments, 2019–2025

Across 102 payments — averaging $3072.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$174K
  • Janssen Research & Development, LLC$82K
  • Amgen$24K
  • Boehringer Ingelheim International GmbH$23K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K

What the payments were for

  • Consulting fees$23,23863%
  • Speaking & faculty fees$7,99622%
  • Travel & lodging$2,1746%
  • Food & beverage$3,1759%
  • Education$320%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,615 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024
$220,187
Medicare patients
861
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$195,979
JardianceEmpagliflozin52$71,181
EntrestoSacubitril/Valsartan55$70,645
XareltoRivaroxaban29$37,038
Repatha SureclickEvolocumab26$20,678
Rosuvastatin Calcium358$6,800
Valsartan93$4,262
Metoprolol Succinate220$3,751
Atorvastatin Calcium256$3,161
Eplerenone28$2,148
Potassium Chloride40$1,883
Amlodipine Besylate187$1,463
Ezetimibe71$1,406
Carvedilol109$1,128
Pravastatin Sodium64$1,068

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →